{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:27:42Z","timestamp":1787052462895,"version":"build-2736575974"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologic therapies have transformed the management of severe chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in patients with uncontrolled type 2 inflammation. Although dupilumab, omalizumab, mepolizumab, benralizumab, tezepelumab, depemokimab, and stapokibart have demonstrated substantial clinical efficacy, the optimal duration and maintenance strategy for biologic therapy remain uncertain. The chronic nature of CRSwNP and the high cost of biologic treatment have stimulated growing interest in dose tapering and treatment de-escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the current evidence on biologic dose tapering in CRSwNP, summarize published tapering strategies, evaluate clinical outcomes, and discuss patient selection, monitoring, and future research priorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review of the published literature on biologic dose tapering and treatment optimization in CRSwNP, including pivotal clinical trials, prospective observational studies, real-world cohorts, and current guideline recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Current evidence, derived predominantly from prospective observational studies and real-world cohorts, suggests that gradual extension of biologic dosing intervals can maintain disease control in carefully selected patients with sustained remission. Most studies reported preserved improvements in nasal polyp score, symptom burden, olfactory function, asthma control, and quality of life after extending treatment from every 2 weeks to every 4 weeks, with some patients successfully maintaining remission at 6-, 8-, 10-, or 12-week intervals. However, available evidence remains predominantly observational, and tapering protocols, eligibility criteria, and definitions of remission are heterogeneous.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Biologic dose tapering represents a promising treatment optimization strategy for carefully selected patients with stable CRSwNP, particularly those receiving dupilumab. However, standardized tapering protocols and high-quality randomized controlled trials are required before routine implementation. Future research should focus on biomarker-guided patient selection, long-term clinical outcomes, and the cost-effectiveness of biologic dose optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fsurg.2026.1933488","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:53:18Z","timestamp":1787050398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose tapering and treatment de-escalation of biologic therapies in chronic rhinosinusitis with nasal polyps: a narrative review"],"prefix":"10.3389","volume":"13","author":[{"given":"Salma S.","family":"AlSharhan","sequence":"first","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, College of Medicine, Imam Abdulrahman Bin Faisal University","place":["Dammam, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain J.","family":"Aljubran","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery, Aljaber Ophthalmology and Otolaryngology Hospital, Alahsa Health Cluster","place":["Alahsa, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/rhin20.600","article-title":"European Position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMcp1800215","article-title":"Chronic rhinosinusitis with nasal polyps","volume":"381","author":"Hopkins","year":"2019","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jaci.2018.03.004","article-title":"Endotype-driven care pathways in patients with chronic rhinosinusitis","volume":"141","author":"Bachert","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic rhinosinusitis with nasal Polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/all.13984","article-title":"Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"75","author":"Bachert","year":"2020","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/03007995.2024.2434083","article-title":"Dupilumab improves sense of smell and clinical outcomes in patients with severe chronic rhinosinusitis with nasal polyps with anosmia","volume":"41","author":"Lane","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1016\/j.jaip.2023.04.054","article-title":"The management of chronic rhinosinusitis with nasal polyps (CRSwNP) with biologics","volume":"11","author":"Wautlet","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2025.12515","article-title":"Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps: the CROWNS-2 randomized clinical trial","volume":"334","author":"Shen","year":"2025","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/19458924221147758","article-title":"Biologics for nasal polyps: synthesizing current recommendations into a practical clinical algorithm","volume":"37","author":"Godse","year":"2023","journal-title":"Am J Rhinol Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab treatment for chronic rhinosinusitis with nasal polyps demonstrate enduring efficacy established during the first six months","volume":"78","author":"van Der Lans","year":"2023","journal-title":"Allergy"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1111\/all.16579","article-title":"Two-Year data of tapered dupilumab shows high effectiveness in chronic rhinosinusitis with nasal polyps with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease","volume":"80","author":"Elzinga","year":"2025","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/lary.32162","article-title":"Dupilumab monthly dose De-escalation maintains efficacy in CRSwNP: a two-year real-world study","volume":"135","author":"De Corso","year":"2025","journal-title":"Laryngoscope"},{"key":"B21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item sinonasal outcome test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/alr.21410","article-title":"Investigation of change in cardinal symptoms of chronic rhinosinusitis after surgical or ongoing medical management","volume":"5","author":"DeConde","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jama.2015.7544","article-title":"Medical therapies for adult chronic sinusitis: a systematic review","volume":"314","author":"Rudmik","year":"2015","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","article-title":"Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective","volume":"56","author":"Edwards","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/msc.1404","article-title":"Tapering biologic therapy for people with rheumatoid arthritis in remission: a review of patient perspectives and associated clinical evidence","volume":"17","author":"Stamp","year":"2019","journal-title":"Musculoskelet Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11926-024-01137-w","article-title":"Dose tapering and discontinuation of biologic DMARDs in axial spondyloarthritis: a narrative review","volume":"26","author":"Chaudhary","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.14309\/ajg.0000000000000783","article-title":"Effectiveness of dose de-escalation of biologic therapy in inflammatory bowel disease: a systematic review","volume":"115","author":"Little","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13223-023-00823-1","article-title":"Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada","volume":"19","author":"Yong","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100412","DOI":"10.1016\/j.jacig.2025.100412","article-title":"Effectiveness of dupilumab treatment against refractory eosinophilic chronic rhinosinusitis","volume":"4","author":"Nakashima","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.413","article-title":"Increasing the dosing interval of dupilumab in patients with severe asthma and chronic rhinosinusitis with nasal polyps","author":"Carbonell Mart\u00ednez","year":"2025","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3342\/kjorl-hns.2024.00101","article-title":"Efficacy and safety of dupilumab for chronic rhinosinusitis with nasal polyps: a retrospective study of every month injection","volume":"68","author":"Kang","year":"2024","journal-title":"Korean J Otorhinolaryngol Head Neck Surg"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1002\/lary.70037","article-title":"Effectiveness and safety of dupilumab monotherapy in Japanese patients with chronic rhinosinusitis with nasal polyps","volume":"135","author":"Fujieda","year":"2025","journal-title":"Laryngoscope"},{"key":"B36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/alr.70125","article-title":"Dosing interval extension of dupilumab in CRSwNP: five-year real world outcomes","volume":"16","author":"Campion","year":"2026","journal-title":"Int Forum Allergy Rhinol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/ph19060961","article-title":"Extension of dupilumab injection intervals in chronic rhinosinusitis with nasal polyps: a real-world study","volume":"19","author":"Habenbacher","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00106-024-01487-y","article-title":"Chronic rhinosinusitis with nasal polyps-extension of dupilumab treatment intervals","volume":"72","author":"Appel","year":"2024","journal-title":"HNO"},{"key":"B39","doi-asserted-by":"publisher","first-page":"765","DOI":"10.4193\/Rhin25.151","article-title":"De-escalation of dupilumab for chronic rhinosinusitis with nasal polyps: analysis of outcomes after modified dosing regimen","volume":"63","author":"D\u2019Ascanio","year":"2025","journal-title":"Rhinology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1007\/s00405-025-09677-2","article-title":"Evaluation of extended dupilumab dosing intervals Q2W (biweekly) versus Q4W (monthly) in chronic rhinosinusitis with nasal polyposis: a real-world study from Saudi Arabia: extended dupilumab dosing in CRSwNP","volume":"282","author":"Alghamdi","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/all.70032","article-title":"Two-Year turning point with dupilumab in chronic rhinosinusitis with nasal polyps: control, remission, and tapering dosage","volume":"81","author":"De Corso","year":"2026","journal-title":"Allergy"},{"key":"B42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/17476348.2022.2090342","article-title":"Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management","volume":"16","author":"Caminati","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1111\/all.15517","article-title":"The changes of eosinophil counts in patients after treatment of dupilumab: a systematic review and meta-analysis","volume":"77","author":"Zhou","year":"2022","journal-title":"Allergy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","article-title":"EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"c5146","DOI":"10.1136\/bmj.c5146","article-title":"Implementing shared decision making in the NHS","volume":"341","author":"Elwyn","year":"2010","journal-title":"Br Med J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e70282","DOI":"10.1002\/lio2.70282","article-title":"Biologics for chronic rhinosinusitis with nasal polyposis: current landscape and future directions","volume":"10","author":"Chiu","year":"2025","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost utility analysis of dupilumab versus endoscopic Sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"131","author":"Scangas","year":"2021","journal-title":"Laryngoscope"},{"key":"B50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/RHU.0000000000002321","article-title":"Effectiveness, tolerability, and safety of mepolizumab injection spacing in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study","volume":"32","author":"Ayano","year":"2026","journal-title":"J Clin Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"100703","DOI":"10.1016\/j.waojou.2022.100703","article-title":"Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma","volume":"15","author":"B\u00f6lke","year":"2022","journal-title":"World Allergy Organ J"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1933488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:53:19Z","timestamp":1787050399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2026.1933488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":51,"alternative-id":["10.3389\/fsurg.2026.1933488"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2026.1933488","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1933488"}}